Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Invested Capital (2020 - 2025)

Tarsus Pharmaceuticals has reported Invested Capital over the past 6 years, most recently at $415.9 million for Q4 2025.

  • Quarterly results put Invested Capital at $415.9 million for Q4 2025, up 40.31% from a year ago — trailing twelve months through Dec 2025 was $415.9 million (up 40.31% YoY), and the annual figure for FY2025 was $415.9 million, up 40.31%.
  • Invested Capital for Q4 2025 was $415.9 million at Tarsus Pharmaceuticals, up from $407.4 million in the prior quarter.
  • Over the last five years, Invested Capital for TARS hit a ceiling of $415.9 million in Q4 2025 and a floor of $166.7 million in Q4 2021.
  • Median Invested Capital over the past 5 years was $233.8 million (2022), compared with a mean of $264.1 million.
  • Biggest five-year swings in Invested Capital: soared 2402.49% in 2021 and later dropped 28.42% in 2023.
  • Tarsus Pharmaceuticals' Invested Capital stood at $166.7 million in 2021, then rose by 27.35% to $212.3 million in 2022, then grew by 6.82% to $226.8 million in 2023, then surged by 30.67% to $296.4 million in 2024, then surged by 40.31% to $415.9 million in 2025.
  • The last three reported values for Invested Capital were $415.9 million (Q4 2025), $407.4 million (Q3 2025), and $404.7 million (Q2 2025) per Business Quant data.